2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
273
Carcinoma, Non-Small-Cell Lung
244
Carcinoma, Renal Cell
144
Neoplasms
99
Neoplasm Metastasis
99
Squamous Cell Carcinoma of Head and Neck
88
Carcinoma, Hepatocellular
87
Colorectal Neoplasms
82
Lung Neoplasms
77
Stomach Neoplasms
59
Pancreatic Neoplasms
56
Carcinoma, Transitional Cell
50
Hodgkin Disease
47
Urinary Bladder Neoplasms
42
Head and Neck Neoplasms
42
Breast Neoplasms
40
Ovarian Neoplasms
37
Triple Negative Breast Neoplasms
34
Small Cell Lung Carcinoma
33
Brain Neoplasms
33
Sarcoma
32
Prostatic Neoplasms
32
Glioblastoma
32
Kidney Neoplasms
29
Recurrence
28
Multiple Myeloma
25
Esophageal Neoplasms
24
Uveal Melanoma
23
Skin Neoplasms
23
Uterine Cervical Neoplasms
22
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
13
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
dodecyl maltoside
5
Radiotherapy
5
Cystoscopy
5
apaziquone
4
ALT-803
4
tislelizumab
3
5-aminolevulinic acid hexyl ester
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
Administration, Intravesical
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
Nivolumab
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts